Yasmine Wasfi

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis:…

Journal of the American Academy of Dermatology · 2017 · 697 citations

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with…

Journal of the American Academy of Dermatology · 2017 · 594 citations